What is Merck & Co.?
Pharmaceuticals and animal health company with $65.0B 2025 revenue scale and public-market buying capacity.
- Category
- Pharmaceuticals and animal health
- Headquarters
- Rahway, NJ
- Founded
- 1891
- Employees
- 72,000+
- Total funding
- Public company; no VC funding
- Status
- NYSE: MRK; Public company
What is Merck & Co.?
Merck & Co. is a public pharmaceuticals and animal health company headquartered in Rahway, NJ. Merck announced full-year 2025 worldwide sales of $65.0 billion, driven by oncology, vaccines, and animal health.
Merck & Co. operates in pharmaceuticals and animal health with a portfolio that includes Keytruda, Gardasil, Animal Health, Cardiometabolic medicines. Merck announced full-year 2025 worldwide sales of $65.0 billion, driven by oncology, vaccines, and animal health. The company employs about 72,000+ and trades as NYSE: MRK, so its buying motion looks like a regulated enterprise account rather than a startup account.
Its scale comes from clinically regulated products, payer or provider relationships, recurring consumables or services, intellectual property, manufacturing quality systems, and commercial access. Customers and partners evaluate Merck & Co. through clinical outcomes, regulatory execution, supply reliability, reimbursement, data security, and total cost of care.
For sellers, Merck & Co. is a multi-stakeholder account. Procurement, finance, clinical, quality, regulatory, legal, privacy, security, IT, operations, commercial, and business-unit leaders can all influence vendor approval. Strong pitches connect directly to patient impact, compliance, revenue capture, operating leverage, risk reduction, uptime, or measurable productivity.
What does Merck & Co. offer?
Merck & Co. offers products and services across Keytruda, Gardasil, Animal Health, Cardiometabolic medicines and related healthcare workflows.
- Keytruda· Oncology
- Gardasil· Vaccines
- Animal Health· Veterinary
- Cardiometabolic medicines· Therapeutics
- HIV medicines· Therapeutics
- Hospital acute care· Therapeutics
How does Merck & Co. make money?
Merck & Co. earns revenue through regulated healthcare products, services, recurring consumables, software-enabled workflows, market access, and enterprise contracts.
Merck & Co. earns revenue from products and services sold to healthcare systems, clinicians, payers, labs, pharmacies, governments, distributors, life-science customers, or patients depending on the business line. In 2025, that model produced $65.0B 2025 of reported revenue scale. Growth is tied to product demand, procedure or test volumes, prescription access, installed-base utilization, new indications, geographic reach, and disciplined pricing.
Pricing is not a public self-serve tier. It is negotiated by therapy, device, test, payer coverage, account type, contract term, service level, GPO or distributor structure, reimbursement, and geography. The practical tiers are enterprise account segmentation, clinical evidence review, value-analysis committee approval, data/security review, legal terms, and renewal or tender economics.
Vendors should expect mature procurement and high evidence requirements. Budgets open when a proposal helps Merck & Co. improve launch execution, manufacturing resilience, clinical operations, data quality, regulatory readiness, patient access, field productivity, cybersecurity, or cost-to-serve.
Who leads Merck & Co.?
Merck & Co. is led by Rob Davis, with finance, R&D, commercial, technology, medical, operations, and business-unit leaders shaping major enterprise decisions.
- Rob DavisChairman and Chief Executive OfficerCEO since 2021Leads Merck's next growth phase as Keytruda matures and new launches scale.
- Caroline LitchfieldChief Financial OfficerCFO since 2021Oversees finance, capital allocation, and investor planning.
- Dean Y. LiPresident, Merck Research LaboratoriesR&D leader since 2021Runs discovery, clinical development, and pipeline strategy.
- Joseph RomanelliPresident, Human Health InternationalSenior commercial leaderLeads international human-health commercialization.
How do you contact Merck & Co.'s leadership?
Merck & Co. publishes official Merck investor-relations contact route, but it does not publish verified personal executive emails for the leaders listed here. Use the official investor, media, supplier, compliance, or contact form routes rather than guessed personal addresses.
official Merck investor-relations contact route; personal executive email format not verifiedHow much funding has Merck & Co. raised?
Merck & Co. is a mature public company, not a venture-backed startup. It trades as NYSE: MRK and funds growth through operating cash flow, public-market access, debt markets, partnerships, and acquisition capacity.
Merck & Co.'s capital history is a public-company story rather than a disclosed venture-round history. The relevant funding events are founding, public listing, major acquisitions or divestitures, retained earnings, debt capacity, R&D reinvestment, manufacturing investment, and shareholder capital allocation.
As of June 2026, the current capital lens is NYSE: MRK, $65.0B 2025 of 2025 revenue scale, and management's ability to fund launches, facilities, technology, clinical programs, supply chain, compliance, and business development. That is materially different from a startup where the next round controls hiring and tool budgets.
Seller signal: Merck & Co. has enterprise buying power, but budget access is tied to risk, ROI, auditability, executive sponsorship, and integration fit. Procurement is more likely to approve projects that reduce operational friction, protect regulated workflows, improve patient or customer outcomes, or support a named business priority.
How did Merck & Co. get here?
Merck & Co. grew through founding, product expansion, public-market scale, strategic portfolio moves, and regulated healthcare execution.
- 1891U.S. Merck incorporatedMerck's U.S. business begins in New Jersey.
- 1940sMajor antibiotics eraThe company scales important anti-infective manufacturing and research.
- 2014Keytruda approvedKeytruda becomes a central oncology growth platform.
- 2021Rob Davis becomes CEOMerck transitions leadership to Rob Davis.
- 2025$65.0B salesMerck announces $65.0 billion of full-year worldwide sales.
- 2026Newer launches emphasizedMerck highlights contributions from newer medicines and vaccines.
Who are Merck & Co.'s competitors?
Merck & Co. competes with large healthcare, pharma, diagnostics, life-science, and medtech companies that overlap in products, customers, procurement budgets, and clinical workflows.
- PfizerCompetes in oncology, vaccines, infectious disease, and global pharma accounts.
- Bristol Myers SquibbCompetes in oncology, immunology, cardiovascular, and hematology.
- RocheCompetes in oncology, diagnostics-enabled medicine, and hospital systems.
- AstraZenecaCompetes in oncology, respiratory, immunology, and global R&D.
- NovartisCompetes in specialty medicines, cardiovascular, and oncology.
- SanofiCompetes in vaccines, immunology, rare disease, and global public-health channels.
Merck & Co. — frequently asked questions
